Keystone Bio
PrivateLast Round
Debt
Mar 11, 2022
Total Funding Raised
$5M
Company Overview
Keystone Bio is a biotherapeutics company that develops diagnostics and therapeutics for inflammation-driven diseases such as Alzheimer's and heart disease by targeting the oral pathogen Porphyromonas gingivalis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Keystone Bio Comparables
Compare Keystone Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lighthouse Pharmaceuticals | 82% | |
| Denteric | 78% | |
| ProMIS Neurosciences Inc. | 64% | |
Keystone Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Mar 11, 2022 | ||||
| Series A | Apr 29, 2019 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 29, 2019
$5M round completed.
Keystone Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Keystone Bio's valuation, stock price, and market status.